Imiquimod

Dermatologic Clinics

Volumn 21, Issue 2, 2003, Pages 291-300

  Skinner Jr , Robert B ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD;

CONDYLOMA ACUMINATUM; DRUG MECHANISM; DRUG STRUCTURE; HERPES SIMPLEX; HUMAN; LEISHMANIASIS; MOLLUSCUM CONTAGIOSUM; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA VIRUS INFECTION; VERRUCA VULGARIS; WART VIRUS;

EID: 0038071490     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(02)00094-3     Document Type: Review

References (69)

1. Slade HB, Owens ML, Tomai MA, et al. Imiquimod 5% cream (Aldara). Exp Opin Invest Drugs 1998;7:437-49.
2. Tomai MA, Gibson SJ, Imbertson LM, et al. Immunomodulating and antiviral activities of the imidazoquinolone S-28463. Antiviral Res 1995;28:253-64.
3. Wagner TL, Horton VL, Carlson GL, et al. Induction of cytokines in cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463. Cytokine 1997;9:837-45.
4. Imbertson LM, Beaurline JM, Couture AM, et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol 1998;110:734-9.
5. Gibson SJ, Elrod SV, Miller RL, et al. Oral R837 induces alpha interferon in cynomolgus monkeys [abstract]. J Interferon Res 1990;10:5124.
6. th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1986.
7. Reiter MJ, Testerman TL, Miller RL, et al. Cytokine induction in mice by the immunomodulator imiquimod. J Leukoc Biol 1994;55:234-40.
8. Wick KA, Kvam DC, Weeks CE, et al. Oral R-837 induces interferon in healthy volunteers [abstract]. Proc Am Assoc Cancer Res 1991;32:257.
9. Dahl MV. An immune response modifier. J Am Acad Dermatol 2000;43:S1-5.
10. Bernstein DI, Miller RL, Harrison CJ. Effects of therapy with an immunomodulator (imiquimod R837) alone and with acylovir on genital HSV-2 infection in guinea pigs when begun after lesion development. Antiviral Res 1993;20:45-55.
11. Harrison CJ, Jenski L, Voychehovski T, et al. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. Antiviral Res 1988;10:209-23.
12. th Interscience Conference on Antimicrobial Agents Chemotherapy, 1985.
13. Harrison CJ, Miller RL, Bernstein DI. Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs. Antimicrob Agents Chemother 1994;38:2059-64.
14. Kende M, Lupton HW, Canonico PG. Treatment of experimental viral infections with immunomodulators. Adv Biosci 1988;68:51-63.
15. Chen M, Griffith RP, Lucia HL, et al. Efficacy of S-26308 against guinea pig cytomegalovirus infection. Antimicrob Agents Chemother 1988;32:678-83.
16. Megyeri K, Au WC, Rosztoczy I, et al. Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by Sendai virus utilize similar signal transduction pathways. Mol Cell Biol 1995;15:2207-18.
17. Miller R, Birmachu W, Gerster J, et al. Imiquimod cytokine induction and antiviral activity. Int Antiviral News 1995;3:111-3.
18. Gibson SJ, Imbertson LM, Wagner TL, et al. Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. J Interferon Cytokine Res 1995;15:537-45.
19. Hsieh CS, Macatonia SE, Tripp CS, et al. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993;260:547-9.
20. Trinchieri G. Interleukine-12 and its role in the generation of TH1 cells. Immunol Today 1993;14:335-8.
21. Wagner TL, Ahonen CL, Couture AM, et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R848 and imiquimod. Cell Immunol 1999;191:10-9.
22. Parronchi P, DeCarli M, Manetti R, et al. II-4 (alpha and gamma) exert opposite regulatory effects on the development of cytolytic potential by TH1 or TH2 human T cell clones. J Immunol 1992;149:2977-83.
23. Parronchi P, Mohapatra S, Sampognaro S, et al. Effects of interferon-alpha on cytokine profile, T cell receptor repertoire and peptide reactivity of human allergen-specific T cells. Eur J Immunol 1996;26:697-703.
24. Burns Jr RP, Ferbel B, Tomai M, et al. The imidazoquinolones, imiquimod and R-848 induce functional, but not phenotypic, maturation of human Langerhans' cells. Clin Immunol 2000;94:13-23.
25. Suzuki H, Wang B, Shivji GM, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans' cells. J Invest Dermatol 2000;114:135-41.
26. Tomai MA, Imbertson LM, Stanczak TL, et al. The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell Immunol 2000;203:55-65.
27. Tyring S. Imiquimod applied topically: a novel immune response modifier. Skin Therapy Lett 2001;6:1-4.
28. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 My088-dependent signaling pathway. Nat Immunol 2002;3:196-200.
29. Read RC, Wyllie DH. Toll receptors and sepsis. Curr Opin Crit Care 2001;7:371-5.
30. Fife KH, Ferenczy A, Douglas Jr JM, et al. Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily or three times a day. Sex Transm Dis 2001;28:226-31.
31. Beutner KR, Spruance SL, Hougham AJ, et al. Treatment of genital warts with an immune-ressponse modifier (imiquimod). J Am Acad Dermatol 1998;38:230-9.
32. Edwards L, Ferenczy A, Eron L, et al. Self administered topical 5% imiquimod cream for external genital warts. HPV Study Group. Human Papilloma Virus. Arch Dermatol 1998;134:25-30.
33. Beutner KR, Tyring SK, Trofatter KF, et al. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother 1998;42:789-94.
34. Tyring SK, Arany T, Stanley MA, et al. A randomized, controlled molecular study of condylomata acuminata clearance during treatment with imiquimod. J Infect Dis 1998;178:551-5.
35. Syed TA, Hadi SM, Qureshi ZA, et al. Treatment of external genital warts in men with imiquimod 2% cream. A placebo-controlled, double-blind study. J Infect 2000;41:148-51.
36. Gilson RJ, Shupack JL, Friedman-Kien AE, et al. A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. AIDS 1999;13:2397-404.
37. Garland SM, Sellors JW, Wikstrom A, et al. Imiquimod 5% cream is a safe and effective self-applied treatment for anogenital warts-results of an open-label multicentre phase III B trial. Int J STD AIDS 2001;12:722-9.
38. O'Mahony C. Difficult wart cases - use of imiquimod cream 5%. Int J STD AIDS 2001;12:400-3.
39. Eggleton S, Tang A. Management of difficult anogenital warts. Sex Trans Infect 1999;75:449-50.
40. Weinberg JM, Stewart A, Stem JO. Successful treatment of extensive condyloma accuminata of the inguinal area and thigh with topical imiquimod cream. Acta Derm Venerol 2001;81:76-7.
41. Maitland JE, Maw R. An audit of patients who have received imiquimod cream 5% for the treatment of anogenital warts. Int J STD AIDS 2000;11:268-70.
42. Hengge UR, Stark R. Topical imiquimod to treat intraepidermal carcinoma. Arch Dermatol 2001;137:709-11.
43. Moresi JM, Herbert CR, Cohen BA. Treatment of anogenital warts in children with topical 0.05% Podofilox gel and 5% imiquimod cream. Pediatr Dermatol 2001;18:448-50.
44. Schaen L, Mercurio MG. Treatment of human papilloma virus in a 6-month-old infant with imiquimod 5% cream. Pediatr Dermatol 2001;18:450-2.
45. Wagman FA, Estape RE, Angiolo R, et al. Self-administered topical 5% imiquimod cream for external anogenital warts in adolescent girls. Obstet Gynecol 2001;97(4 Suppl 1):S14.
46. Nelson AL. The importance of patient and healthcare provider perceptions in the evaluation of imiquimod and other prior treatments for anogenital warts. Int J STD AIDS 2002;13:29-35.
47. O'Mahony C, Law C, Gollick HP, et al. New patient applied therapy for anogenital warts is rated favorably by patients. Int J STD AIDS 2001;12:565-70.
48. Kuwahara RT, Skinner Jr RB. Granuloma annulare resolved with topical application of imiquimod. Pediatr Dermatol 2002;19(4):368-71.
49. Langley PC, Tyring SK, Smith MH. The cost effectiveness of patient-applied versus provider-administered intervention strategies for the treatment of extragenital warts. Am J Manag Care 1999;5:69-77.
50. Hengge UR, Esser S, Schultewolter T, et al. Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum. Br J Dermatol 2000;143:1026-31.
51. Sparling JD, Checketts SR, Chapman MS. Imiquimod for plantar and periungual warts. Cutis 2001;68:397-9.
52. Weisshaar E, Gollnick H. Potentiating effect of imiquimod in the treatment of verrucae vulgares in immunocompromised patients. Acta Derm Venerol 2000;80:305-7.
53. Rinne D, Linhart C, Schofer H. Lip papillomatosis in immunodeficiency: therapy with imiquimod. Br J Dermatol 2000;142:196-7.
54. Schwab RA, Elston DM. Topical imiquimod for recalcitrant flat warts. Cutis 2000;65:160-2.
55. Oster-Schmidt C. Imiquimod: a new possibility for treatment of resistant verrucae planae. Arch Dermatol 2001;137:666-7.
56. Bernstein DI, Miller RL, Harrison CJ. Adjuvant effects of imiquimod on a herpes simplex virus 2 glycoprotein vaccine in guinea pigs. J Infect Dis 1993;167:731-5.
57. Gilbert J, Drehs MM, Weinberg JM. Topical imiquimod for acyclovir-unresponsive herpes simplex virus 2 infection. Arch Dermatol 2001;137:1015-7.
58. Liota E, Smith KJ, Buckley R, et al. Imiquimod therapy for molluscum contagiosum. J Cutan Med Surg 2001;4:76-82.
59. Syed TA, Goswami J, Ahmadpour OA, et al. Treatment of molluscum contagiosum in males with an analog of imiquimod 1% cream. A placebo-controlled doubleblind study. J Dermatol 1998;25:309-13.
60. Barba AR, Kapoor S, Berman B. An open label safety study of topical imiquimod 5% cream in the treatment of molluscum contagiosum in children. Dermatol Online J 2001;7:20.
61. Skinner RB, Ray S, Talinin NY. Treatment of molluscum contagiosum with topical 5% imiquimod cream. Pediatr Dermatol 2000;17(5):420.
62. Brown Jr CW. Recalcitrant molluscum contagiosum in an HIV-afficated male treated successfully with topical imiquimod. Cutis 2000;65:363-6.
63. Strauss RM, Doyle EL, Mohsen AH, et al. Successful treatment of molluscum contagiosum with topical imiquimod in a severly immunocompromised HIV-positive patient. Int J STD AIDS 2001;12:264-6.
64. Stokes JR, Sorkness RL, Kaplan MR, et al. Attenuation of virus-induced airway dysfunction in rats treated with imiquimod. Eur Respir J 1998;11:324-9.
65. Castleman WL, Brundage-Anguish LJ, Kreitzer L, et al. Pathogenesis of bronchiolitis and pneumonia induced in neonatal and weanling rats by parainfluenza (Sendai) virus. Am J Pathol 1987;129:277-86.
66. Arevalo I, Ward B, Miller R, et al. Successful treatment of drug-resistant cutaneous leishmaniasis by use of imiquimod, an immunomodulator. Clin Inf Dis 2001;33:1847-51.
67. th Annual Meeting. Washington DC, March 2001.
68. Kahn AM. Imiquimod as adjunct for vitilgo (letter). J Clin Dermatol 1998;1:8-9.
69. Cutler K, Kagen MH, Don PC, et al. Treatment of facial verrucae with topical imiquimod cream in a patient with human immunodeficiency virus. Acta Derm Venerol 2000;80:134-5.